HPA Axis Suppression and Corticosteroid Complications
Mechanism of HPA Axis Suppression
Exogenous corticosteroids suppress ACTH and endogenous cortisol production through negative feedback inhibition at both the hypothalamus and pituitary gland, mimicking the physiologic cortisol feedback mechanism but at supraphysiologic levels. 1
The pathophysiology operates through three distinct temporal mechanisms 2:
- Fast feedback (minutes): Non-genomic membrane effects that inhibit stimulus-secretion coupling, blocking CRF-induced ACTH release without affecting basal secretion
- Intermediate feedback (hours): Requires corticosteroid-dependent protein synthesis, inhibiting both CRH and ACTH release in response to stimulation
- Slow feedback (days-weeks): Classic genomic mechanism that reduces pituitary ACTH content by decreasing POMC mRNA levels, ultimately suppressing both basal and stimulated ACTH secretion
Why ACTH Concentrations Diminish
ACTH levels decrease because exogenous glucocorticoids directly inhibit CRH production in the hypothalamus and ACTH synthesis in pituitary corticotroph cells. 1 Prolonged supraphysiologic glucocorticoid exposure causes:
- Pro-apoptotic effects on pituitary corticotroph cells 1
- Protein degradation manifesting as Crooke's hyaline changes 1
- Reduced anterior pituitary responsiveness 1
- Secondary adrenal cortex atrophy from chronic ACTH deficiency 1
The suppression is dose-dependent and occurs with doses exceeding physiologic equivalents (>15-25 mg hydrocortisone or >4-6 mg prednisone daily) for ≥3-4 weeks 1. During tapering, ACTH remains suppressed initially, then gradually recovers as glucocorticoid doses decrease, followed by eventual cortisol recovery—though complete recovery may remain impaired in some patients 1.
Corticosteroids and Multifocal Motor Neuropathy (MMN)
Corticosteroids do NOT typically cause MMN; rather, MMN is an immune-mediated neuropathy that paradoxically may worsen with steroid treatment in most cases, though rare steroid-responsive variants exist. 3
This question contains a conceptual error. MMN is characterized by:
- Progressive asymmetric limb weakness with motor conduction blocks
- Anti-GM1 ganglioside antibodies
- Standard treatment with intravenous immunoglobulins (NOT steroids)
However, one case report 3 documented a steroid-responsive MMN variant with cranial manifestations responding to low-dose prednisolone. This represents an exceptional presentation rather than a causal relationship.
The more relevant steroid-induced neuropathy is diabetic peripheral neuropathy secondary to steroid-induced diabetes (addressed below), not MMN.
Bone Degradation Mechanism
Corticosteroids cause bone loss through multiple direct mechanisms: inhibiting osteoblast function and bone formation, promoting osteoblast and osteocyte apoptosis, decreasing calcium absorption, increasing renal calcium excretion, and inducing secondary hyperparathyroidism. 1
The evidence demonstrates:
- Even low-dose glucocorticoids (prednisone 2.5-7.5 mg/day) significantly increase osteoporosis and fracture risk 1
- A British cohort showed elevated fracture rates in rheumatoid arthritis patients on average prednisone 5.8 mg/day 1
- Risk increases with both higher daily doses and cumulative exposure 1
Additional contributing factors include:
- Steroid-induced myopathy increasing fall risk
- Decreased sex hormone production
- Impaired vitamin D metabolism
Hair Loss Mechanism
Corticosteroids cause hair loss through disruption of the hair growth cycle, shifting follicles prematurely from anagen (growth phase) to telogen (resting phase), resulting in telogen effluvium. This occurs via:
- Direct effects on hair follicle keratinocytes
- Altered local growth factor production
- Protein catabolism affecting hair matrix cells
- Potential effects on androgen metabolism
The hair loss typically manifests 2-3 months after initiating high-dose corticosteroid therapy and may be diffuse or patchy.
Pathway to Diabetic Neuropathy from Corticosteroid Use
Corticosteroids induce diabetic neuropathy through a sequential pathway: corticosteroids cause insulin resistance and impaired insulin secretion → hyperglycemia (steroid-induced diabetes) → metabolic and vascular nerve damage → peripheral neuropathy. 4, 5
Detailed Mechanistic Pathway:
Step 1: Corticosteroid-Induced Metabolic Dysfunction
- Corticosteroids increase insulin resistance in muscle, liver, and adipose tissue 4
- Impair pancreatic beta-cell insulin secretion 4
- Increase hepatic gluconeogenesis
- Promote lipolysis and elevated triglycerides 6
Step 2: Hyperglycemia Development
- Steroid diabetes occurs in 20% (range 10-60%) of corticosteroid-treated patients 4
- Hyperglycemia is predominantly postprandial, peaking in afternoon/evening 4
- Fasting glucose may remain normal initially, making diagnosis challenging 4
Step 3: Neuropathy Development The case report 5 illustrates this timeline: A patient developed diabetes 1 month after prednisolone initiation, then peripheral neuropathy 3 months later with numbness, weakness, and EMG-confirmed nerve impairment.
Mechanisms of nerve damage include:
- Metabolic pathway: Hyperglycemia activates polyol pathway → sorbitol accumulation → osmotic nerve damage and oxidative stress
- Vascular pathway: Microvascular damage reduces nerve blood flow (vasa nervorum ischemia)
- Advanced glycation end-products (AGEs): Protein glycation damages nerve structure
- Inflammatory pathway: Elevated triglycerides and insulin resistance markers (TG/HDL ratio, TyG index) correlate with neuropathy severity 6
Step 4: Clinical Manifestations
- Distal symmetric polyneuropathy (most common)
- Sensory symptoms: numbness, paresthesias, pain
- Motor symptoms: weakness, muscle cramps 5
- Autonomic dysfunction in severe cases
Critical Clinical Considerations:
- Diagnosis requires postprandial glucose monitoring or OGTT, as fasting glucose has low sensitivity 4
- Steroid-induced diabetes dramatically worsens outcomes: 60% increased rejection rates in transplant recipients, 90% increased mortality, and 150% higher annual costs 4
- Neuropathy can develop rapidly (within 3 months) once hyperglycemia occurs 5
- Treatment requires discontinuing/tapering steroids when possible, intensive glycemic control, and neuropathic symptom management (e.g., mecobalamin, gabapentinoids) 5
The association between insulin resistance markers and bone health 6 suggests overlapping pathophysiology—insulin resistance contributes to both neuropathy and bone degradation, compounding fracture risk through decreased bone mineral density and increased falls from neuropathy.